CSF2 and neoplasm: In phase Ib trial of tumor lysate DC vaccines, DC-vaccines, manufactured via co-culturing peripheral blood mononuclear cells with granulocyte macrophage-colony stimulating factor and IL-4 and loaded with tumor lysate/keyhole limpet hemocyanin, have not resulted in clinical response in patients with metastatic melanoma (169).